Research console · stable gastric pentadecapeptide
BPC-157 has been studied for muscle, tendon, and soft-tissue recovery across decades of preclinical work.
A registered readout of the literature: the cytoprotection base layer, the muscle and tendon recovery studies, the VEGFR2-Akt-eNOS mechanism, the pharmacokinetics, the three small human pilots, and where compounded access stands today.
What the BPC-157 literature has measured
BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence of a protein found in human gastric juice. Its authors call it a stable gastric pentadecapeptide, and across three decades of animal work it has produced one repeated result: accelerated repair of injured tissue. In a fully transected rat Achilles tendon, BPC-157 improved biomechanical, functional, microscopic, and macroscopic recovery against untreated controls [1]. In crushed rat gastrocnemius muscle, it sped functional and structural recovery [5]. In a gastric-ulcer model it cut ulcer area and rebuilt glandular epithelium [4].
The evidence stack is deep at the bottom and thin at the top. The preclinical base — cytoprotection, tendon, muscle, the angiogenesis mechanism, and a 2022 pharmacokinetic characterization — is broad and reproducible. The human layer is three small uncontrolled pilot studies [9][10][11]. This site prints each finding on the layer it belongs to, so the dense rodent base and the barely-printed human top are visible at a glance.
This is an editorial digest of the published record. It is not a clinic, it sells nothing, and it issues no instructions for use. Every quantitative claim below links to a study on the study references and citations page.
BPC-157: a stable gastric pentadecapeptide
The BPC-157 peptide is a chain of fifteen amino acids: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, molecular formula C62H98N16O22, molecular weight 1419.53 Da, CAS 137525-51-0. It is synthetic and stable rather than a hormone the body circulates; the parent Body Protection Compound was isolated from gastric juice, and BPC-157 is a stable fragment of it.
The word stable is load-bearing. Authors report the peptide holds together in human gastric juice, which is why oral and peroral interest persists [7]. Its repair effects in animal models are most consistently tied to angiogenesis — the growth of new blood vessels — via the VEGFR2-Akt-eNOS mechanism [3].
What does BPC-157 do in the body?
In animal models BPC-157 is described as cytoprotective, meaning it protects cells and tissue from injury. Its repair effects are most consistently linked to angiogenesis through VEGFR2-Akt-eNOS signaling and modulation of the nitric-oxide system [3]. Reported actions are concentrated in tissue protection and healing, not in any single organ.
Is BPC-157 a growth hormone?
No. It is a synthetic 15-amino-acid peptide, not a hormone. It has been reported to up-regulate growth-hormone-receptor expression in tendon fibroblasts at the mRNA and protein level, which is a signaling effect on a receptor, not the action of a growth hormone itself.
Does BPC-157 work immediately?
Onset is not established in humans. Animal healing studies dose once daily over days to weeks, and the peptide's elimination half-life is under 30 minutes in rat and dog pharmacokinetics [2]. There is no validated human time-to-effect.
What BPC-157 has been studied for (reported research effects)
Read as reported preclinical research effects — never as human benefit claims — the BPC-157 record clusters in a few areas. Tendon: accelerated healing of a transected Achilles tendon with better collagen organization [1]. Muscle: faster recovery after crush injury [5], and restored healing in a corticosteroid-impaired model [6]. Gut: reduced gastric-ulcer area, with an ulcer-formation inhibition ratio of 45.7-65.6% at the higher tested doses [4]. Vasculature: increased vessel density and faster blood-flow recovery in ischemic muscle, driven by VEGFR2 up-regulation [3].
These are the documented research effects. The benefits people search for that the literature does not support are equally worth stating plainly: there is no published evidence for muscle building, weight loss, or raised testosterone. The muscle and tendon recovery studies are about repair, not growth.
Can BPC-157 help with weight loss?
No. Weight-loss claims are not supported by the published BPC-157 literature and should be treated skeptically. No controlled study reports a weight-loss effect; the documented research is about tissue protection and repair.
How does BPC-157 make you feel?
Subjective effects are not characterized in controlled human research. Central-nervous-system effects — serotonergic and antidepressant-like signals — are reported only in rodent models, so there is no validated account of how the peptide feels in people.
Where the human evidence actually stands
Human data on BPC-157 is limited to three small, uncontrolled pilots. A two-participant intravenous safety pilot infused up to 20 mg with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers [9]. An intra-articular case series reported reduced knee pain across several pain types, with no comparator [8]. A 12-patient intravesical pilot in interstitial cystitis reported symptom resolution in 10 of 12 patients after a single dose during cystoscopy [11].
A 2025 narrative review reached the honest summary: broad preclinical support, only three human pilot studies, no rigorous large-scale trials, and BPC-157 best regarded as investigational [10]. That is the shape of the field — a deep animal base, a thin human top. The human pilot studies and the open questions are detailed on the research page.